International Deals

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists. At

By | January 12, 2006

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists. At the same time, European venture capitalists are expressing concern with the inability to find local IPO exits for many of their companies and are looking to the US to find better investees. Anonymous Quote of the Day: ?A good biotech CEO is like a bullfighter: he possesses agility, grace, courage to stare danger in the face and only the remote prospect of being paid well if he survives.?

Popular Now

  1. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  2. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. EPO Revokes Broad’s CRISPR Patent
    The Nutshell EPO Revokes Broad’s CRISPR Patent

    Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely—and more are likely to follow.

AAAS